<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="include virustatic agents that have already been approved for the" exact="treatment" post="of other types of viral infection, as well as"/>
 <result pre="the virus from docking to this receptor is a conceivable" exact="treatment" post="approach. Transmembrane protease serine 2 (TMPRSS2) plays a role"/>
 <result pre="urgent questions are being asked about vaccines to prevent coronavirus" exact="infection" post="and virustatics for effective treatment. Over 80 clinical trials"/>
 <result pre="of the human body. Potential candidates for the prevention and" exact="treatment" post="of coronavirus infection are therefore peptides or small-molecular substances"/>
 <result pre="body. Potential candidates for the prevention and treatment of coronavirus" exact="infection" post="are therefore peptides or small-molecular substances that block the"/>
 <result pre="an inhibitor of this protease, is licensed in Japan for" exact="treatment" post="of chronic pancreatitis (4), but no clinical trials of"/>
 <result pre="pancreatitis (4), but no clinical trials of camostat in coronavirus" exact="infection" post="have yet been conducted. Among the clinical trials initiated"/>
 <result pre="investigating the administration of recombinant ACE2 enzyme to treat the" exact="infection" post="(table 1). Soluble ACE2 might slow the spread by"/>
 <result pre="the efficacy and tolerability of chloroquine in the prevention and" exact="treatment" post="of COVID-19 (table 1). Vaccination strategies Although vaccination strategies"/>
 <result pre="vaccine for MERS, but no finished vaccine for this coronavirus" exact="infection" post="ever became available. In any case, it will take"/>
 <result pre="is extremely important (7, 8). Potential antiviral treatments No specific" exact="treatment" post="for COVID-19 is yet known, but the search for"/>
 <result pre="from immunomodulatory approaches with immunoglobulins, interferon, thalidomide, and glucocorticoids to" exact="treatment" post="with virustatics such as oseltamivir, darunavir, and umifenovir, which"/>
 <result pre="darunavir, and umifenovir, which was developed in Russia for the" exact="treatment" post="of influenza (table 1). In view of the possibility"/>
 <result pre="SARS-CoV-2 with new properties, including resistance to certain substances. Glucocorticoid" exact="treatment" post="was tried two decades ago in patients with SARS,"/>
 <result pre="in combination with glucocorticoids. Clinically and also radiologically confirmed successful" exact="treatment" post="was reported, but none of the studies included a"/>
 <result pre="such as lopinavir and nelfinavir, that were developed for the" exact="treatment" post="of HIV infection. The protease inhibitor lopinavir has been"/>
 <result pre="virus excretion was seen (13). A detailed report of the" exact="treatment" post="of a 35-year-old man with COVID-19 in the USA"/>
 <result pre="5 March 2020 (14). This was the first instance of" exact="treatment" post="with the as yet unlicensed nucleoside analog remdesivir. The"/>
 <result pre="the symptoms he was admitted to the hospital. The initial" exact="treatment" post="was unspecific, with antipyretics such as ibuprofen and paracetamol."/>
 <result pre="be expected in a few weeks. Unresolved issues in antiviral" exact="treatment" post="No specific treatment has yet been developed for coronavirus"/>
 <result pre="a few weeks. Unresolved issues in antiviral treatment No specific" exact="treatment" post="has yet been developed for coronavirus infections, despite the"/>
 <result pre="abbreviated by neuraminidase inhibitors such as oseltamivir, but only if" exact="treatment" post="is initiated very early. As a number of placebo-controlled"/>
 <result pre="activity. Dissemination of the virus persisted for longer in the" exact="treatment" post="group than in the placebo group (15). Decades later,"/>
 <result pre="for possible use against hepatitis B. In both cases, the" exact="treatment" post="had to be discontinued owing to toxicity with long-term"/>
 <result pre="was abandoned (16, 17). Trials of various combinations for HIV" exact="infection" post="were also discontinued because the treatments were insufficiently effective"/>
 <result pre="be advisable in such cases and whether early initiation of" exact="treatment" post="would be essential. This requires careful consideration of the"/>
 <result pre="it first becomes clear after a few days whether the" exact="infection" post="is spreading to the lower respiratory tract, i.e., whether"/>
 <result pre="necessary to determine whether efficacy can be demonstrated also when" exact="treatment" post="is commenced later. The in-vitro activity of different substances"/>
 <result pre="relatively weak effect (EC50: 96 ÂµM). Favipiravir, licensed for the" exact="treatment" post="of influenza in Japan, exhibited moderate activity, as did"/>
 <result pre="of nitazoxanide, a drug that was developed mainly for the" exact="treatment" post="of protozoal infections but also acts against some bacteria"/>
 <result pre="and other substances against COVID-19 (table 1). Since no specific" exact="treatment" post="for this infection has yet been established, and in"/>
 <result pre="against COVID-19 (table 1). Since no specific treatment for this" exact="infection" post="has yet been established, and in the light of"/>
 <result pre="their inclusion criteria, e.g., severity of disease and time from" exact="diagnosis" post="to randomization. The first trials are expected to reach"/>
 <result pre="medications mentioned in this article is yet licensed for the" exact="treatment" post="of COVID-19. Any administration of drugs approved for other"/>
 <result pre="known whether any of the the substances currently undergoing clinical" exact="testing" post="will prove to be beneficial and have no adverse"/>
 <result pre="beneficial and have no adverse effects. Conclusion The outbreak of" exact="infection" post="with a novel coronavirus is the latest reminder of"/>
 <result pre="to inhibit the new coronavirus SARS-CoV-2 in vitro. Since no" exact="treatment" post="has yet proved efficacious, the strengths and weaknesses of"/>
 <result pre="coronavirus in Wuhan, ChinaLancet202039549750631986264 11RussellCDMillarJEBaillieJKClinical evidence does not support corticosteroid" exact="treatment" post="for 2019-nCoV lung injuryLancet202039547347532043983 12YoungBEOngSWXKalimuddinSet al.Epidemiologic features and clinical"/>
 <result pre="endoplasmic reticulum Table 1 Selected clinical trials on prevention and" exact="treatment" post="of COVID-19 with licensed drugs or substances under clinical"/>
 <result pre="human ACE2 i.v. daily, max. 7 days12 patients with standard" exact="treatment" post="24 First Affiliated Hospital of Guangzhou Medical University China"/>
 <result pre="ACE2, Angiotensin-converting enzyme 2; CT, computed tomography; i.v., intravenous; PCR," exact="polymerase chain reaction;" post="rh, recombinant human Table 2 Action of different substances"/>
 <result pre="clinical trials in COVID-19 0.77 Chloroquine 4-Aminoquinoline derivative; prevention and" exact="treatment" post="of malaria, also in rheumatoid arthritis; antiviral action due"/>
 <result pre="Favipiravir Pyrazine carboxamide, inhibits viral RNA-dependent RNA polymerase, licensed for" exact="treatment" post="of influenza in Japan 62 Penciclovir Nucleoside analog, guanosine"/>
 <result pre="inhibits viral DNA polymerase; its prodrug famciclovir is licensed for" exact="treatment" post="of herpes zoster 96 Ribavirin Nucleoside analog, guanosine derivative,"/>
 <result pre="and RNA viruses; also has an immunomodulatory action; licensed for" exact="treatment" post="of chronic hepatitis C 109 EC50 = Concentration with"/>
</results>
